MARKET

PHVS

PHVS

Pharvaris N.V.
NASDAQ
22.77
+1.52
+7.15%
Closed 16:00 04/25 EDT
OPEN
20.74
PREV CLOSE
21.25
HIGH
24.00
LOW
19.59
VOLUME
82.37K
TURNOVER
0
52 WEEK HIGH
33.00
52 WEEK LOW
7.93
MARKET CAP
1.23B
P/E (TTM)
-7.8517
1D
5D
1M
3M
1Y
5Y
Bullish Two Hundred Day Moving Average Cross - PHVS
NASDAQ · 2d ago
Weekly Report: what happened at PHVS last week (0415-0419)?
Weekly Report · 4d ago
Pharvaris Is Maintained at Overweight by Morgan Stanley
Dow Jones · 04/15 16:56
Pharvaris Price Target Cut to $34.00/Share From $35.00 by Morgan Stanley
Dow Jones · 04/15 16:56
Morgan Stanley Maintains Overweight on Pharvaris, Lowers Price Target to $34
Benzinga · 04/15 16:45
Weekly Report: what happened at PHVS last week (0408-0412)?
Weekly Report · 04/15 09:21
Pharvaris Earns Buy Rating as Deucrictibant Shows Promising Progress in HAE Treatment
TipRanks · 04/15 01:25
Pharvaris files for automatic mixed securities shelf
Seeking Alpha · 04/12 20:34
More
About PHVS
Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).

Webull offers Pharvaris NV stock information, including NASDAQ: PHVS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PHVS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PHVS stock methods without spending real money on the virtual paper trading platform.